Research programme: opioid analgesics - Antares

Drug Profile

Research programme: opioid analgesics - Antares

Alternative Names: AP-159 - Antares

Latest Information Update: 06 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Antares Pharma
  • Class Pyridines
  • Mechanism of Action Opioid receptor agonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 12 Oct 2007 Antares Pharma signs development and licensing agreement with undisclosed pharmaceutical company for transmucosal opioid analgesic product
  • 29 Nov 2006 Preclinical trials in Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top